SLC5A2 and hydrops fetalis: Along with a reduction in erythropoiesis and the hematocrit levels, it is estimated that the use of SGLT-2 inhibitors in patients with DM type 2 with HF reduces the risk of HF decompensation and hospitalization via decrease in preload, afterload, left ventricle wall stress, myocardial hypertrophy, cardiac muscle demands on O2 as well as via cardiac fibrosis inhibition and the prevention of the development of arrhythmiogenic mechanisms [109,110,114].